Arteriopathy and Endothelial Function
Endothelial Dysfunction Reversibility in Patients With Peripheral Arterial Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Olivier Rouyer, MD
- Phone Number: 33.3.88.11.61.22
- Email: olivier.rouyer@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67091
- Recruiting
- Service de Chirurgie Vasculaire
-
Contact:
- Fabien Thaveau, MD
- Phone Number: 33.3.88.11.60.68
- Email: fabien.thaveau@chru-strasbourg.fr
-
Principal Investigator:
- Fabien Thaveau, MD
-
Sub-Investigator:
- Nabil Chakfe, MD
-
Sub-Investigator:
- Jean-Georges Kretz, MD
-
Strasbourg, France, 67091
- Recruiting
- Service de Physiologie et d'Explorations Fonctionnelles
-
Contact:
- Olivier Rouyer, MD
- Phone Number: 33.3.88.11.61.22
- Email: olivier.rouyer@chru-strasbourg.fr
-
Principal Investigator:
- Olivier Rouyer, MD
-
Sub-Investigator:
- Bernard Geny, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Peripheral arteriopathy
- Stable cardio-respiratory status
Exclusion Criteria:
- Dialysis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: fruit juice
300 mL of fruit juice
|
absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
|
|
Placebo Comparator: placebo
300 mL of fruit juice without polyphenols
|
absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Endothelial function 1 hour after taking the juice
Time Frame: 1 hour after taking the juice
|
1 hour after taking the juice
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Relationship between reversibility of the endothelial function and the patient's prognosis at 3 years
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Olivier Rouyer, MD, Hopitaux Universitaires de Strasbourg
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 3801
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.